This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia and Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RDE) of BR101801 in patients with relapsed/refractory advanced hematologic malignancies except acute leukemia and multiple myeloma. The Phase Ib (dose expansion) part of the study is designed to assess tumor response and safety in specific advanced relapsed/refractory hematologic malignances at a dose of BR101801 identified in Phase Ia. Patients will receive BR101801 capsules orally, daily, in 28-day cycles.  For Phase Ia the planned doses are 50, 100, 200, 325, and 450 mg. Phase Ib will consist of 3 different cohorts of different cancer types, and the dosage is based on the results for Ia. 

(BR-101801-CT-101, IRB 2020-0010)

IRB 2020-0649
A Phase I, Open-label Multi-dose Two-Part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438), and the Effects of a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat in Subjects with Advanced Malignancies
IRB 2020-0315
Phase 1b/II trial combining PD1 inhibition (pembrolizumab) and cesium 131 brachytherapy with salvage surgery to enhance immunogenicity and improve local control in head and neck cancer
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!

An upgrade to the High Enroll mobile app will be available to UC Cancer Center members and outside affiliates in March 2021. The app will have a new look and exciting new features to support the recruitment of patients into our research studies.

The UC Cancer Center continues to partner with High Enroll, LLC, to make recruitment easier and more enjoyable. We hope you will find the updated mobile application even more helpful. The new app will continue to provide all the information you need at your fingertips for discussing research with a patient. Some of the new features include: more content fields for each study; updates on studies via push notifications; the ability to save a study as a “favorite”; the ability to share a specific study with an interested colleague; and the ability to provide scheduled coordinator contact coverage 24/7.


The upgraded version of the mobile app is available for anyone at UC or beyond. It takes only seconds to get the new app. You can scan the QR code above, download it directly from the App Store, or wait for us to provide you a download link from the previous High Enroll app.


If you have any questions, please research out to your UC Cancer Center research team or High Enroll at 513.993.0330



Dylan and Ginger

WVXU: UC researchers invents lab-on-a-chip device for cancer

Leyla Esfandiari, an assistant professor of biomedical and electrical engineering in UC's College of Engineering and Applied Science, has a patent pending on a small lab-on-a-chip device that can help doctors get accurate results without invasive biopsies. This is a noninvasive, point-of-care device for early cancer screening using a small amount of a patient’s body fluid such as saliva or blood. 
Click Here to Visit the UC Newsroom
Division of Hematology Oncology Grand Rounds Schedule
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Questions?  Please call us at 513-584-7698, or email us!
Copyright © 2019, All rights reserved.

UC Cancer Center Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA